Big Money Sentiment decreased to 1.07 in 2018 Q4. It has change of 0.08, from 2018Q3’s 1.15. The ratio worsened due to Sage Therapeutics, Inc. positioning: 44 sold and 60 reduced. 35 funds took positions and 76 increased positions. Investors holded 46.64 million in 2018Q3 but now own 47.40 million shares or 1.62% more.
Citadel Advisors Limited Liability Company accumulated 30,317 shs. Partner Fund Mngmt Lp accumulated 505,776 shs. Amalgamated State Bank accumulated 10,168 shs. Geode Cap Management Ltd Limited Liability Company reported 0.01% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE). Northern Tru Corp invested in 0.01% or 220,176 shs. Marshall Wace Limited Liability Partnership has invested 0.07% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE). New York-based M&R Capital has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Charles Schwab Invest Mngmt Inc accumulated 186,607 shs. 44 are held by Pnc Fincl Services Group Inc Inc. First Republic Inv Management reported 2,404 shs. Victory Mngmt Incorporated reported 463,541 shs. Tekla Ltd Liability reported 0.4% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Earnest Prtn Ltd reported 24 shs stake. Vanguard Grp Inc Inc owns 4.02M shs. Manufacturers Life Ins Co The reported 0.03% of its capital in Sage Therapeutics, Inc. (NASDAQ:SAGE).

Sage Therapeutics, Inc. registered $4.45 million net activity with 0 insider buys and 2 insider sales since January 23, 2019. Kanes Stephen sold $3.44M worth of stock or 22,948 shs.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Ratings Coverage

Total analysts of 7 have positions in Sage Therapeutics (NASDAQ:SAGE) as follows: 6 rated it a “Buy”, 1 with “Sell” and 0 with “Hold”. The positive are 86%. Since October 11, 2018 according to StockzIntelligence Inc Sage Therapeutics has 10 analyst reports. The company rating was maintained by Morgan Stanley on Thursday, October 11. On Wednesday, December 19 Morgan Stanley maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) with “Overweight” rating. The stock rating was maintained by Morgan Stanley with “Buy” on Monday, February 25. On Wednesday, February 20 the company was maintained by RBC Capital Markets. In Monday, November 5 report RBC Capital Markets maintained the stock with “Outperform” rating. On Tuesday, February 19 the stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Buy” rating given by Piper Jaffray. In Tuesday, February 19 report Oppenheimer maintained it with “Buy” rating and $170 target. The stock rating was maintained by Cowen & Co with “Buy” on Tuesday, February 19. Listed here are Sage Therapeutics, Inc. (NASDAQ:SAGE) PTs and latest ratings.

25/02/2019 Broker: Morgan Stanley Rating: Buy New Target: $215 Maintain
22/02/2019 Broker: Guggenheim Rating: Buy New Target: $205 Initiates Coverage On
20/02/2019 Broker: RBC Capital Markets Rating: Buy New Target: $249 Maintain
19/02/2019 Broker: Cowen & Co Rating: Buy New Target: $207 Maintain
19/02/2019 Broker: Oppenheimer Rating: Buy New Target: $170 Maintain
19/02/2019 Broker: Piper Jaffray Rating: Buy New Target: $206 Maintain
19/12/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $230 New Target: $213 Maintain
13/11/2018 Broker: Leerink Swann Rating: Underperform New Target: $80 Initiates Coverage On
05/11/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $259 New Target: $261 Maintain
11/10/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $228 New Target: $230 Maintain

SAGE is reaching $150.91 during the last trading session, after increased 0.27%.Sage Therapeutics, Inc. has volume of 311,604 shares. Since March 10, 2018 SAGE has declined 3.58% and is downtrending. SAGE underperformed the S&P500 by 7.95%.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders.The company has $7.69 billion market cap. The Company’s lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus , as well as for the treatment of post-partum depression (PPD).Last it reported negative earnings. The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus.

For more Sage Therapeutics, Inc. (NASDAQ:SAGE) news brought out briefly go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Benzinga.com or Streetinsider.com. The titles are as follows: “25 Stocks Moving In Tuesday’s Pre-Market Session – Benzinga” brought out on February 26, 2019, “Here’s Why Sage Therapeutics Gained 48.9% in January – Nasdaq” on February 10, 2019, “Dow Grabs 8th Straight Weekly Win on Trade-Deal Hopes – Nasdaq” with a publish date: February 15, 2019, “Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote – Benzinga” and the last “After-Hours Movers 02/25: (HTZ) (THC) (ETSY) Higher; (VTGN) (NVCN) (IMMU) (more…) – StreetInsider.com” with publication date: February 25, 2019.